Atrial Natriuretic Peptide (ANP) Suppress λ-Carrageenan-Induced Acute Paw Edema by Modulating Pro-inflammatory Genes in Swiss Albino Mice

• Published in: International journal of peptide research and therapeutics Vol. 28; no. 5
• Main Authors: Kalaiarasu, Lakshmi Priya, Babu, Aadhil Ashwaq, Krishnan, Kalaiselvi, Dhanusu, Suresh, Vellaichamy, Elangovan
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 05-08-2022; Springer Nature B.V
• Subjects: Animal Anatomy; Anti-inflammatory agents; Aspirin; Atrial natriuretic peptide; Biochemistry; Biomedical and Life Sciences; Body weight; Carrageenans; Cyclooxygenase-2; Cytokines; Edema; Histology; Inflammation; Interleukin 1; Interleukin 6; Latency; Life Sciences; Molecular Medicine; Morphology; Pain; Peptides; Peroxidase; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Polymer Sciences; Prostaglandin E2; Tumor necrosis factor; Tumors; Natriuretic peptide receptor-A (NPR-a); λ-Carrageenan (λ-CAN); Pro-inflammatory and Aspirin (ASP); Anti-inflammatory; Atrial natriuretic peptide (ANP)
• ISSN: 1573-3904; 1573-3149; 1573-3904
• DOI: 10.1007/s10989-022-10444-8

The present study was designed to investigate the anti-inflammatory activity of atrial natriuretic peptide (ANP) using λ-Carrageenan (λ-CAN)—induced acute inflammation in the mice model. A single subplantar injection of λ-CAN (1% in 0.9% saline) triggers acute paw edema. ANP (2 μg/kg body weight/day/i.p) was given 30 min prior or after administration of λ-CAN. The standard drug Aspirin (ASP) treated group was used as a positive control. A marked increase in paw thickness (32.56% p < 0.001) and thermal pain latency (0.82 ± 0.03
vs
3.6 ± 0.12; P < 0.001) were noticed in λ-CAN-induced mice as compared with control. The level of pro-inflammatory marker genes such as Nuclear factor-κB and Cyclooxygenase-2 were significantly increased (p < 0.001 respectively) in λ-CAN-induced mice as compared with control. A similar trend was noticed in pro-inflammatory cytokines such as Interleukin-6, Interleukin-1 beta, Tumour necrosis factor-alpha and Prostaglandin E2 (p < 0.001 respectively). On the contrary, ANP exhibits a marked reduction in paw edema thickness (pre-8.76% and post-9.12%, p < 0.001) and thermal pain latency in both pre-0.82 ± 0.03
vs
1.2 ± 0.06 and post-0.82 ± 0.03
vs
1.6 ± 0.02 (P < 0.001) were noticed in ANP pre-and post-treated group. Further myeloperoxidase activity, pro-inflammatory marker genes and pro-inflammatory cytokines were also reverted (p < 0.01 respectively) to near-normal levels. The present study results suggest that pre-and post-treatment of ANP positively neutralizes the λ-CAN induced acute edematic and inflammatory responses. The anti-edematic and anti-inflammatory action of ANP was found to be much more effective than that of the non-steroidal drug aspirin (ASP).